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Objectives: Mycoplasma genitalium (MG) causes urethritis and cervicitis, potentially causing reproductive
complications. Resistance in MG to ﬁrst-line (azithromycin) and second-line (moxiﬂoxacin) treatment
has increased. We examined the clinical and analytical performance of the new Conformite Europeene
(CE)/in vitro diagnostics (IVD) Aptima Mycoplasma genitalium assay (CE/IVD AMG; Hologic); the preva-
lence of MG, Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG); and MG resistance to azi-
thromycin and moxiﬂoxacin in Denmark, Norway and Sweden in 2016.
Methods: From February 2016 to February 2017, urogenital and extragenital (only in Denmark) speci-
mens from consecutive attendees at three sexually transmitted disease clinics were tested with the CE/
IVD AMG, the research-use-only MG Alt TMA-1 assay (Hologic), Aptima Combo 2 (CT/NG) assay and a
laboratory-developed TaqMan real-time mgpB quantitative real-time PCR (qPCR). Resistance-associated
mutations were determined by sequencing. Strains of MG and other mycoplasma species in different
concentrations were also tested.
Results: In total 5269 patients were included. The prevalence of MG was 7.2% (382/5269; 4.9e9.8% in the
countries). The sensitivity of the CE/IVD AMG, MG Alt TMA-1 and mgpB qPCR ranged 99.13e100%, 99.13
e100% and 73.24e81.60%, respectively, in the countries. The speciﬁcity ranged 99.57e99.96%, 100% and
99.69e100%, respectively. The prevalence of resistance-associated mutations for azithromycin and
moxiﬂoxacin was 41.4% (120/290; 17.7e56.6%) and 6.6% (18/274; 4.1e10.2%), respectively. Multidrug
resistance was found in all countries (2.7%; 1.1e4.2%).
Conclusions: Both transcription-mediated ampliﬁcation (TMA)-based MG assays had a highly superior
sensitivity compared to the mgpB qPCR. The prevalence of MG and azithromycin resistance was high.
Validated and quality-assured molecular tests for MG, routine resistance testing of MG-positive samples
and antimicrobial resistance surveillance are crucial. M. Unemo, Clin Microbiol Infect 2018;24:533
© 2017 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology
and Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).ting Centre for Gonorrhoea and Other STIs, Department of Laboratory Medicine, €Orebro University Hospital, SE-701 85,
e (M. Unemo).
r Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open access article under
g/licenses/by-nc-nd/4.0/).
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Mycoplasma genitalium (MG) frequently causes nongonococcal
urethritis (NGU) in male subjects, and is associated with cervicitis,
pelvic inﬂammatory disease, endometritis and probably infertility
[1e6].
In many countries worldwide, MG testing is limited or lacking,
and increased testing of symptomatic patients in particular is rec-
ommended [4,5]. Nucleic acid ampliﬁcation tests (NAATs) are the
only appropriate diagnostic methods. Many commercially available
and particularly laboratory-developed diagnostic PCRs have been
used [5,7e13]. However, many of these have not been appropriately
validated, and none of the companies providing US Food and Drug
Administrationeapproved, automated NAATs for detection of
Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) have yet
obtained Food and Drug Administration approval for an MG NAAT.
Recently the new Conformite Europeene (CE)/in vitro diagnostics
(IVD)-marked Aptima Mycoplasma genitalium assay (CE/IVD AMG),
targeting 16S rRNA, was commercialized for the Panther system
(Hologic, San Diego, CA, USA). An earlier non-CE/IVD version of this
assay showed promising results in a smaller study which examined
only urine specimens [14].
The ﬁrst-line empiric treatment for male NGU in the 2016 Eu-
ropean NGU guideline is doxycycline 100 mg twice daily or 200 mg
once daily orally for 7 days. Second-line therapy is azithromycin
500 mg in a single dose on day 1 followed by 250 mg daily for
4 days, or azithromycin 1 g in a single dose orally [3]. In the 2016
European MG guideline, the 5-day azithromycin regimen is the
ﬁrst-line treatment in the absence of macrolide resistance or when
the infectious organism's resistance status is unknown. Second-line
treatment is moxiﬂoxacin 400 mg once daily for 7 to 10 days [4,5].
During the recent decade, the azithromycin efﬁcacy for treatment
of MG infections has declined [4,5,15e17]. This macrolide resistance
is primarily caused by mutations at position A2058 or A2059
(Escherichia coli numbering) in the 23S rRNA gene [18]. During the
most recent years, a declining moxiﬂoxacin efﬁcacy has been
documented, particularly in Japan and Australia [4,5,16,17,19e24].
However, surveillance data regarding MG moxiﬂoxacin resistance
remain scarce internationally. Moxiﬂoxacin resistance is associated
with mutations in the quinolone resistanceedetermining region
(QRDR) of the parC gene, primarily at positions S83 and D87 (MG
numbering), whereas mutations in gyrA presumably play a minor
role [23,24].
We performed what is to our knowledge the ﬁrst large-scale
evaluation of the clinical and analytic sensitivity and speciﬁcity of
the new CE/IVD AMG on the Panther system (Hologic), and
described the prevalence of MG, CT, NG and MG resistance-
eassociated mutations for azithromycin and moxiﬂoxacin in un-
selected patients attending sexually transmitted disease (STD)
clinics in Denmark, Norway and Sweden in 2016. For reference
testing, a research-use-only MG transcription-mediated ampliﬁ-
cation (TMA) assay (MG Alt TMA-1 [25]; Hologic), targeting a
different 16S rRNA sequence, and a well-recognized laboratory-
developed TaqMan real-timemgpB qPCR assay, with a sensitivity of
ﬁve genome equivalents (geq)/reaction [11,26], were used. This was
the Nordic Aptima MG Evaluation (NAME) study.
Methods
Patients and biologic specimens
Consecutive male and female subjects attending the STD Clinic
at €Orebro University Hospital, €Orebro, Sweden, from February to
December 2016; Olaﬁa Clinic, Oslo University Hospital, Norway,
from February 2016 to February 2017; and Bispebjerg UniversityHospital, Copenhagen, Denmark, from March to June 2016 were
enrolled into the study after providing informed consent. In-
dividuals attended the clinics because they had symptoms, because
they had had unprotected sex and/or because they had received
partner notiﬁcation. In Sweden and Norway, ﬁrst-void urine (FVU)
was collected from male subjects and two vaginal swabs were
simultaneously collected from female subjects. In Denmark, sam-
ples included urethral, rectal and/or pharyngeal swabs from male
subjects and vaginal, cervical, urethral and/or rectal and pharyngeal
swabs from female subjects according to the clinical indication.
Two millilitres and 8 to 10 mL of the FVU specimens were promptly
transferred to an Aptima Urine Specimen Transport Tube (Hologic)
and an AssayAssure Genelock Urine Collection Tube (0.8 mL; Sierra
Molecular), respectively. Of the two simultaneously collected
vaginal swabs (or the additional specimen types), one was
promptly transferred into an Aptima Vaginal Swab Specimen
Collection tube (Hologic) and the other into Copan UTMmedium (2
mL; Copan). All NAATs were performed in a manner blinded to the
results of the other NAATs and generally 1 week after specimen
collection.
External quality assessment (EQA) panel
An EQUALIS (http://www.equalis.se/en/start/) MG EQA panel
(2016:01; http://www.equalis.se/sv/vaar-verksamhet/extern-kvalite
tssaekring/kvalitetssaekringsprogram/m-r/mycoplasma-genitalium-
nukleinsyra-288/) was also tested. The scheme consisted of twoMG-
negative samples and fourMG-positive samples, i.e. oneMG-positive
urine specimen diluted 101, 102, 103 and 104 in MG-negative
urine.
Analytical inclusivity and speciﬁcity panel
Twenty-ﬁve unique genome-sequenced MG isolates (unpub-
lished data) and 21 strains of 14 other mycoplasma species (human
or phylogenetically closely related) were tested in a blinded
manner with the CE/IVD AMG and MG Alt TMA-1. The non-MG
mycoplasma strains included ﬁve M. pneumoniae (Mac, M129,
M6696, M2060, M6844), three M. amphoriforme (M5572, M6123,
A62), two M. pirum (NCTC 11702, AMRC C-1555 Zeus 8/11 16) and
one each ofM. alvi (Isley),M. arginini (G230),M. buccale (CH20247),
M. fermentans, M. gallisepticum (15302), M. hominis (PG21),
M. lipophilum (Maby), M. orale (Patt), M. penetrans (GTU-54),
M. primatum (Navel) and M. salivarium (PG20). Mycoplasmas were
cultured as previously described [27].
CE/IVD AMG assay
The CE/IVD AMG was performed on a Panther system according
to the manufacturer's instructions (Hologic).
Reference testing
The MG Alt TMA-1 was performed on a Panther system ac-
cording to the manufacturer's instructions (Hologic).
The mgpB qPCR and DNA extraction using Chelex 100 slurry
(Bio-Rad) was performed as previously described [11]. The DNA
extracts were tested the same day or were stored at 20C until
use.
Chlamydia trachomatis and Neisseria gonorrhoeae testing
The Aptima Combo 2 (CT/NG) assay was performed on a Panther
system according to the manufacturer's instructions (Hologic).
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Specimens were considered truly positive if they were positive
in a minimum two of the three MG NAATs. Repeated testing of
specimens with discrepant results was performed.
Detection of resistance-associated mutations
Resistance-associated mutations in the 23S rRNA and parC
genes were identiﬁed using pyrosequencing and conventional
Sanger sequencing, respectively, as described previously [18,23].
Statistical analysis
Fisher's exact test was computed by IBM SPSS Statistics soft-
ware, with signiﬁcance set at p < 0.05.
Ethics
The study was approved by relevant departmental ethics com-
mittees (Regional Committees for Medical and Health Research
Ethics South-East 2016/50, Region Hovedstaden H-15018251).
Results
Patients and Mycoplasma genitaliumepositive samples
In total, 5269 patients were included. Of these, 1273 (507 female
and 766 male subjects), 2547 (721 female and 1826 male subjects)
and 1449 (535 female and 914 male subjects) were from Denmark,
Norway and Sweden, respectively. The median (range) age of theTable 1
Sensitivities, speciﬁcities, PPVs and NPVs of different assays in different specimens [11]
Gender (no. of patients) Specimen (no. of truly positive
ﬁndings/no. of samples)
Assaya No. o
(no. o
Female (1763) Vaginal (138/1683) CE/IVD AMGa 141 (
MG Alt TMA-1a 136 (
mgpB qPCRb 109 (
Cervical (23/280) CE/IVD AMGa 23 (2
MG Alt TMA-1a 21 (2
mgpB qPCRb 18 (1
Urethral (26/290) CE/IVD AMGa 26 (2
MG Alt TMA-1a 25 (2
mgpB qPCRb 13 (1
Rectal (3/37) CE/IVD AMG a 4 (3)
MG Alt TMA-1a 3 (3)
mgpB qPCRb 1 (1)
Pharyngeal (0/74) CE/IVD AMG a 0
MG Alt TMA-1a 0
mgpB qPCRb 0
Male (3506) FVU (165/2740) CE/IVD AMGc 166 (
MG Alt TMA-1c 165 (
mgpB qPCRd 129 (
Urethral (56/754) CE/IVD AMGa 58 (5
MG Alt TMA-1a 54 (5
mgpB qPCRb 38 (3
Rectal (15/237) CE/IVD AMG a 16 (1
MG Alt TMA-1a 15 (1
mgpB qPCRb 8 (8)
Pharyngeal (4/260) CE/IVD AMG a 4 (4)
MG Alt TMA-1a 4 (4)
mgpB qPCRb 1 (1)
AMG, AptimaMycoplasma genitalium assay; CE, Conformite Europeene; FVU, ﬁrst-void uri
positive predictive value; qPCR, quantitative real-time PCR.
a Total of 13% of primary swab sample (400 mL taken from 3 mL Aptima transport me
b Total of 0.5% of primary swab sample analysed in assay after nucleic acid extraction
c Total of 200 mL of primary FVU sample analysed in assay after nucleic acid extractio
d Total of 35 mL of primary FVU sample analysed in assay after nucleic acid extractionmale subjects was 30 (15e79) years and of the female subjects 27
was (16e65) years, with median ages of 29, 28 and 30 years in
Denmark, Norway and Sweden, respectively.
The number of MG-infected patients in Denmark, Norway and
Sweden was 115 (9.0%), 125 (4.9%) and 142 (9.8%), respectively.
Among the total 382 (7.2%) infected patients, the MG prevalence in
male (female) subjects was 8.9% (9.3%), 4.5% (6.0%) and 9.1% (11.0%)
in Denmark, Norway and Sweden, respectively. The CT prevalence
in themale (female) subjects was 10.7% (10.8%), 8.8% (7.5%) and 6.1%
(4.1%) in Denmark, Norway and Sweden, respectively, and the NG
prevalence was 8.3% (3.9%), 0.44% (0.14%) and 0.55% (0.93%),
respectively. In total, 12.4% of MG-positive male subjects were
coinfected with CT (9.9%), NG (1.7%) or CT þ NG (0.8%) and 11.4% of
MG-positive female subjects were coinfected with CT (8.7%), NG
(2.0%) or CT þ NG (0.7%).Clinical sensitivity and speciﬁcity
The sensitivity and speciﬁcity of the CE/IVD AMG when exam-
ining vaginal swabs (n ¼ 1683) were 100% and 99.81%, respectively,
and 95.65% and 99.61%, respectively, for cervical swabs (n ¼ 280).
For male subjects, the sensitivity and speciﬁcity was 100% and
99.96%, respectively, when examining FVU specimens (n ¼ 2740).
For male urethral swabs (n ¼ 754), the sensitivity and speciﬁcity
were 96.43% and 99.43%, respectively (Table 1).
The overall sensitivity, speciﬁcity, positive predictive value and
negative predictive value of the CE/IVD AMG were 99.74% (range in
countries, 99.13e100%), 99.84% (99.57e99.96%), 97.94%
(95.80e99.21%) and 99.98% (99.91e100%), respectively. The overall
sensitivity, speciﬁcity, positive predictive value and negative pre-
dictive value of the MGAlt TMA-1 were 99.74% (99.13e100%), 100%,f positive results
f truly positive results)
Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%)
138) 100 99.81 97.87 99.94
136) 98.55 100 100 99.87
108) 78.26 99.94 99.08 98.09
2) 95.65 99.61 95.65 99.61
1) 91.30 100 100 99.23
8) 78.26 100 100 98.09
5) 96.15 99.62 96.15 99.62
5) 96.15 100 100 99.62
3) 50.00 100 100 95.31
100 97.06 75.00 100
100 100 100 100
33.33 100 100 94.44
NA NA NA NA
NA NA NA NA
NA NA NA NA
165) 100 99.96 99.40 100
165) 100 100 100 100
127) 76.97 99.88 97.69 98.54
4) 96.43 99.43 93.75 99.71
4) 96.43 100 100 99.71
8) 67.86 100 100 97.49
5) 100 99.55 93.75 100
5) 100 100 100 100
53.33 100 100 96.94
100 100 100 100
100 100 100 100
25.00 100 100 98.84
ne; IVD, in vitro diagnostics; NA, not applicable; NPV, negative predictive value; PPV,
dium) analysed in assay after nucleic acid extraction.
.
n.
.
Table 2
Sensitivities, speciﬁcities, PPVs and NPVs based on patient infection status [11]
Assay Population (no. of infected patients/no. of included patients) Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%)
CE/IVD AMG Denmark (115/1273) 99.13 (114/115) 99.57 (1153/1158) 95.80 (114/119) 99.91 (1153/1154)
Norway (125/2547) 100 (125/125) 99.96 (2421/2422) 99.21 (125/126) 100 (2421/2421)
Sweden (142/1449) 100 (142/142) 99.85 (1305/1307) 98.61 (142/144) 100 (1305/1305)
Total (n ¼ 5269) 99.74 (381/382) 99.84 (4879/4887) 97.94 (381/389) 99.98 (4879/4880)
MG Alt TMA-1 Denmark (115/1273) 99.13 (114/115) 100 (1158/1158) 100 (114/114) 99.91 (1158/1159)
Norway (125/2547) 100 (125/125) 100 (2422/2422) 100 (125/125) 100 (2422/2422)
Sweden (142/1449) 100 (142/142) 100 (1307/1307) 100 (142/142) 100 (1307/1307)
Total (n ¼ 5269) 99.74 (381/382) 100 (4887/4887) 100 (381/381) 99.98 (4887/4888)
mgpB qPCR Denmark (115/1273) 73.91 (85/115) 100 (1158/1158) 100 (85/85) 97.47 (1158/1188)
Norway (125/2547) 81.60 (102/125) 100 (2422/2422) 100 (102/102) 99.06 (2422/2445)
Sweden (142/1449) 73.24 (104/142) 99.69 (1303/1307) 96.30 (104/108) 97.17 (1303/1341)
Total (n ¼ 5269) 76.18 (291/382) 99.92 (4883/4887) 98.64 (291/295) 98.17 (4883/4974)
AMG, Aptima Mycoplasma genitalium; CE, Conformite Europeene; FVU, ﬁrst-void urine; IVD, in vitro diagnostics; NA, not applicable; NPV, negative predictive value; PPV,
positive predictive value; qPCR, quantitative real-time PCR.
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(73.24e81.60%), 99.92% (99.69e100%), 98.64% (96.30e100%) and
98.17% (97.17e99.06%), respectively (Table 2).
Both the CE/IVD AMG andMG Alt TMA-1 showed correct results
for all six samples in the EQUALIS MG EQA panel (2016:01). The
mgpB qPCRmissed the two samples with lowest MG concentration.
For comparison, the results for this EQA panel distributed to 29
Scandinavian laboratories is provided in Fig. 1.
Analytical inclusivity and speciﬁcity panel
All 25 MG strains were detected at <10 geq per reaction, and
several strains were detected in concentrations below the limit of
detection for the mgpB PCR assay. All strains of M. amphoriforme
(n ¼ 3), M. pirum (n ¼ 2) and M. alvi (n ¼ 1) were reproducibly
positive in the CE/IVD AMG down to concentrations <50 geq per
reaction. No cross-reaction was observed in the MG Alt TMA-1.
Macrolide resistanceeassociated mutations
Macrolide resistanceeassociated 23S rRNA gene mutations
were detected in 41.4% of samples (39.3% (68/173) and 44.4% (52/
117) in male and female samples, respectively) (Table 3).
The 23S rRNA gene mutation A2059G was predominant in
Denmark (53.5% of mutated samples) and Norway (59.6%), while0
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Fig. 1. Results of 29 Scandinavian diagnostic laboratories and CE/IVD Aptima Mycoplasma ge
as Aptima MG because both assays detected 100% of positive samples) when testing EQUA
equalis.se/en). CE, Conformite Europeene; IVD, in vitro diagnostics.A2058G (50.0%) was slightly more common in Sweden. The
A2059G and A2058G mutations accounted for 96.7% of mutated
samples (Table 3).
Moxiﬂoxacin resistanceeassociated mutations
The rate of possible ﬂuoroquinolone resistanceeassociated parC
QRDR mutations was 6.6% (88.9% of samples from male subjects)
(Table 4).
Themost frequent parC QRDR amino acid alterationswere D87N
(n¼ 5) and S83N (n¼ 5), followed by S83I (n¼ 4) and D87H (n¼ 3).
These parC alterations accounted for 94.4% of mutated samples
(Table 4).
Multidrug resistance
In Denmark, Sweden and Norway, three (4.2%), three (3.1%) and
one (1.1%) sample, respectively, comprised both macrolide and
possible ﬂuoroquinolone resistanceeassociated mutations
(Table 5).
Discussion
In what is to our knowledge the ﬁrst large-scale prospective
evaluation of a novel test (including 5269 consecutiveNeg. Neg.
e urine
Participating
labs (n=29)
Aptima MG
nitalium assay (CE/IVD AMG) and MG Alt TMA-1 assay (this study; collectively referred
LIS Mycoplasma genitalium external quality assessment panel (2016:01; http://www.
Table 3
Prevalence of macrolide resistanceeassociated 23S rRNA gene mutations in Myco-
plasma genitaliumepositive samples in Denmark, Norway and Sweden
Mutationa Frequencyb
Denmark Norway Sweden Total
A2059G 30.3 (23/76) 33.7 (34/101) 8.0 (9/113) 22.8 (66/290)
A2058G 26.3 (20/76) 19.8 (20/101) 8.8 (10/113) 17.2 (50/290)
A2058T d 2.0 (2/101) 0.9 (1/113) 1.0 (3/290)
A2059C d 1.0 (1/101) d 0.3 (1/290)
Wild type 43.4 (33/76) 43.6 (44/101) 82.3 (93/113) 58.6 (170/290)
Nontypeable 9 24 29 62
Total mutated 56.6 (43/76) 56.4 (57/101) 17.7 (20/113) 41.4 (120/290)
a Nucleotide positions in 23S rRNA gene are given according to Escherichia coli
numbering.
b Frequency data are presented as % (no. of samples with mutations/no. of suc-
cessfully sequenced samples). Only one sample per positive patient included.
Table 4
Prevalence of possible ﬂuoroquinolone resistanceeassociated parC mutations
(mutations in QRDR of parC) in Mycoplasma genitaliumepositive samples in
Denmark, Norway and Sweden
Mutationa Frequencyb
Denmark Norway Sweden Total
D87Nc d 2.0 (2/98) 3.1 (3/98) 1.8 (5/274)
S83Nd 1.3 (1/78) d 4.1 (4/98) 1.8 (5/274)
S83Ic 2.6 (2/78) 1.0 (1/98) 1.0 (1/98) 1.5 (4/274)
D87H d 1.0 (1/98) 2.0 (2/98) 1.1 (3/274)
S83Rc 1.3 (1/78) d d 0.4 (1/274)
WT, silent or outside QRDR 95 (74/78) 96 (94/98) 90 (88/98) 93 (256/274)
Nontypeable 10 27 44 81
Total mutated 5.1 (4/78) 4.1 (4/98) 10.2 (10/98) 6.6 (18/274)
MIC, minimum inhibitory concentration; QRDR, quinolone resistanceedetermining
region (estimated at parC amino acid codons 80e90); WT, wild type.
a Amino acid positions in parC are given according to M. genitalium numbering.
b Frequency data are presented as % (no. of samples with mutations/no. of suc-
cessfully sequenced samples). Only one sample per positive patient included.
c Mutations where in vitro MIC determination has demonstrated signiﬁcantly
elevated MICs of moxiﬂoxacin.
d One strain evaluated had moxiﬂoxacin-susceptible phenotype (Jensen et al.,
unpublished data).
Table 5
Prevalence of Mycoplasma genitaliumepositive samples with possible multidrug
resistance (both 23S rRNA gene and parC resistanceeassociated mutations) in
Denmark, Norway and Sweden
Mutation Frequencya
Denmark Norway Sweden Total
MRAM and D87N 1.1 (1/92) 2.1 (2/97) 1.2 (3/260)
MRAM and S83N 1.4 (1/74) 1.0 (1/97) 0.8 (2/260)
MRAM and S83R 1.4 (1/74) 0.4 (1/260)
MRAM and S83I 1.4 (1/74) 0.4 (1/260)
MRAM and WT,
silent or outside QRDR
52.7 (39/74) 54.3 (50/92) 17.5 (17/97) 106/263
Total mutated 4.2 (3/71) 1.1 (1/92) 3.1 (3/97) 2.7 (7/260)
MRAM, macrolide resistanceeassociated mutation; QRDR, quinolone resis-
tanceedetermining region (estimated at parC amino acid codons 80e90); WT, wild
type.
a Frequency data are presented as % (no. of samples with mutations/no. of suc-
cessfully sequenced samples). Only one sample per positive patient included.
M. Unemo et al. / Clinical Microbiology and Infection 24 (2018) 533e539 537symptomatic and asymptomatic patients in the three Scandina-
vian countries), the new CE/IVD AMG showed a high clinical and
analytical sensitivity and speciﬁcity when used to examine uro-
genital and extragenital specimens. The clinical sensitivity
(99.74%) was signiﬁcantly higher compared to the mgpB qPCR
(76.18%). MG infections frequently have low bacterial loads, i.e.
100 times lower compared to CT infections [28], and for theseinfections, the Aptima MG assays, using larger volume of the
primary sample (Table 1), target capture of 16S rRNA (up to
100e1000 copies per cell) and TMA, likely have a superior clinical
sensitivity compared to any PCRs targeting single- or multiple-
copy genes.
The sensitivity examining recommended vaginal swabs [4] was
higher (100%), with high speciﬁcity (99.81%), compared to invasive
cervical (95.65%) and urethral swabs (96.15%), which is consistent
with previous studies [4,5,29]. For male subjects, the sensitivity
examining recommended FVU specimens [4] was also higher
(100%) compared to invasive urethral swabs (96.43%). However,
these differences were not signiﬁcant as a result of the small
number of samples. The sensitivity examining rectal swabs was
100% in both genders.
The clinical speciﬁcities of the CE/IVD AMG (99.84%) and MG
Alt TMA-1 (100%) were also high. For the ﬁrst time, the analytical
speciﬁcity of these MG assays was comprehensively investigated
as well. Surprisingly, all strains of M. amphoriforme, M. pirum and
M. alvi were detected in low concentrations in the CE/IVD AMG,
while the MG Alt TMA-1 showed 100% analytical speciﬁcity. The
knowledge regarding these mycoplasma species and their preva-
lence in human specimens is limited. M. alvi has been found
mainly in the bovine gastrointestinal tract, and this cross-reaction
appears clinically irrelevant [30]. M. pirum is considered an HIV-
associated mycoplasma species [31] that has been found in
rectal specimens from men who have sex with men [32]. Four
male urethral swabs (0.5%) were positive only in the CE/IVD AMG,
but this ﬁnding might only reﬂect a lower limit of detection of this
assay. Nevertheless, particularly for HIV-positive men who have
sex with men, a positive CE/IVD AMG rectal test might have to be
treated with caution. M. amphoriforme has been found in patients
with primary antibody deﬁciency [33] and respiratory infections
[34], but evidence of disease associations is lacking. None of the
pharyngeal swabs (n ¼ 334) tested positive only in the CE/IVD
AMG. Consequently, based on this as well as the overall clinical
speciﬁcity of 99.84% of the CE/IVD AMG, the clinical relevance of
possible cross-reactivity with these three mycoplasma species
appears to be minimal.
The prevalence of MG was signiﬁcantly higher in Denmark
(9.0%) and Sweden (9.8%) compared to Norway (4.9%) (p < 0.05). At
the Olaﬁa Clinic, Norway, comprehensive MG testing, treatment
and contact notiﬁcation for both symptomatic and asymptomatic
individuals have been performed since 2005 (as for CT), and
consequently MG prevalence might have declined. Overall, MG was
very common, which might be because MG is, at least in Denmark
and Sweden, not routinely tested for in all attendees of STD clinics.
Macrolide resistance was signiﬁcantly less prevalent in Sweden
(18%) compared to Norway (56%) and Denmark (57%) (p < 0.05).
This likely reﬂects that azithromycin 1 g, which effectively induces
or selects for macrolide resistance, has been used as ﬁrst-line
treatment for NGU and CT infections in Denmark and Norway
for many years. In Sweden, doxycycline has always been the
recommended ﬁrst-line treatment for these infections. On the
basis of the high resistance levels to macrolides in Scandinavia
and internationally [4,5,15e17], and the frequent selection of
resistance during azithromycin treatment, a test of cure after
>3 weeks is crucial even in patients infected with macrolide-
susceptible MG strains [4]. Furthermore, ideally, macrolide resis-
tance testing should be performed on all MG-positive samples
before treatment is initiated [4,5]. The level of potential moxi-
ﬂoxacin resistanceeassociated mutations was relatively low in
Scandinavia, but it is increasing. It was higher in Sweden (10.2%)
compared to Denmark (5.1%) and Norway (4.1%). However, the
parC S83N alteration accounted for 40% of the mutations in
Sweden, and this alteration might not signiﬁcantly increase the
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L for one isolate; Jensen et al., unpublished data). Moxiﬂoxacin
resistanceeassociated mutations were mainly detected in male
subjects (88.9%). This might indicate that these male subjects
belong to a high-frequency transmitting population and have
repeatedly been treated with moxiﬂoxacin for MG infection or
persistent NGU suspected to be due to MG. This hypothesis needs
further detailed testing. Studies in Japan and Australia have shown
high prevalences of parC QRDR mutations, with treatment failure
of moxiﬂoxacin [4,5,16,17,20e22,24]. In our study, potentially
multidrug-resistant MG was found in all countries (2.7%;
1.1e4.2%). Multidrug resistance in MG is a major concern. Pristi-
namycin is the only third-line treatment available [4], but it is not
100% effective [21].
Major strengths of our study include using a large sample size
(5269 patients); testing both urogenital and extragenital specimens
from consecutive symptomatic and asymptomatic individuals in
three countries (demographic and geographic diversity) which
effectively assess the NAATs and provide reliable MG, CT and NG
prevalence ﬁgures; using three different NAATs on all specimens to
detect truly infected patients; and sequencing for both macrolide
and ﬂuoroquinolone resistance. Limitations include that details
regarding the patients' demographics, risk factors, and presenting
clinical signs and symptoms were unavailable.
In conclusion, the new CE/IVD AMG assay performed in the fully
automated Panther system showed a high clinical sensitivity and
speciﬁcity, and it offers a simple, rapid, sensitive and speciﬁc MG
diagnostics which can easily be combined with detection of CT, NG
and Trichomonas vaginalis. ThemgpB reference PCR missed >20% of
positive samples, which emphasizes the fact that earlier published
MG prevalence ﬁgures internationally are underestimated and
many patients may have received false-negative results. However,
as for all commercially available NAATs, the cost per test of the CE/
IVD AMG assay is signiﬁcantly higher than laboratory-developed
diagnostic PCRs, e.g. the mgpB PCR used in this study, and in gen-
eral it is crucial to ensure that appropriate NAATs are also affordable
in less-resourced settings. Routine resistance testing of all MG
positive samples, at least for macrolide resistanceeassociated 23S
rRNA gene mutations, test of cure after >3 weeks, and regular na-
tional and international surveillance of MG resistance are all
imperative. Furthermore, use of doxycycline instead of azi-
thromycin for empirical ﬁrst-line therapy of NGU is recommended
[3,5]. The importance of several parC mutations as well as the
possible impact of gyrA mutations on moxiﬂoxacin MICs remain
largely unknown, and culturing samples with MG strains carrying
mutations in order to associate to phenotypic resistance should be
prioritized. Finally, novel antimicrobials for MG treatment are
essential. For example, lefamulin, gepotidacin and zoliﬂodacin
deserve further attention, and dual antimicrobial therapy needs to
be considered [5].Transparency Declaration
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